Highlighted Article – Nutlin-3, A P53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment – Mini-Reviews in Medicinal Chemistry

MRMC- Articles_17-18-Voon Yee-Lin

To access this article, please visit: http://www.eurekaselect.com/154246

 

Wishing A Very Happy Birthday to Dr. Atta-ur-Rahman!

Dr. Atta-ur-Rahman

Dr. Atta-ur-Rahman, FRS

Editor-in-Chief: Current Organic ChemistryMini Reviews in Medicinal ChemistryCurrent Medicinal Chemistry

Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

Wishing A Very Happy Birthday to M. Iqbal Choudhary!

M. Iqbal choudhary

M. Iqbal Choudhary

EDITOR-IN-CHIEF: Mini-Reviews in Medicinal Chemistry

H.E.J. Research Institute of Chemistry
University of Karachi
Karachi
Pakistan

Press Release for EurekAlert! Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment

This article by Dr. Voon Yee-Lin et al. is published in Mini-Reviews in Medicinal Chemistry, Volume 17, 2017

 

Nasopharyngeal carcinoma (NPC) is a common epithelial squamous cell head and neck cancer which is strongly associated with gamma herpes Epstein-Barr virus infection and the intake of salted fish. NPC incidence remain significantly high among men in the populations of Southern China, Hong Kong, Taiwan, Northern Africa and Southeast Asia. It has claimed many thousands of lives worldwide with approximately 80,000 new cases diagnosed annually and a mortality rate that exceeds 50,000. There are several approaches to fight NPC, which include surgery, radiation therapy and chemotherapy. NPC treatment remain one of the most intractable challenge for medicine. Radiation therapy alone has failed to provide a significant improvement in the overall survival rate of NPC, compared to chemotherapy. Radiocurable NPC is still dependent on concurrent treatment of megavoltage radiation with chemo drugs. Chemo-resistance persists as the major challenge in the management of patients diagnosed with metastatic NPC. In view of these challenges, it is understandable that scientists are trying to discover p53-based targeted therapy which could be applied as effective NPC therapies.

Recent discoveries have demonstrated that utilizing Nutlin-3 as a p53 activator is promising strategy for cancer management in the future. This review describes the potential use of newly discovered anticancer molecule Nutlin-3 and the future directions of its clinical research for NPC treatment. Nutlin-3 specifically targets p53-Mdm2 interaction and offers new therapeutic opportunities by enhancing cancer cell growth arrest and apoptosis through the restoration of the p53-mediated tumor suppression pathway while producing minimal cytotoxicity and side effects. In this regard, restoration of p53 tumor suppressor gene with Nutlin-3 could be explored for the discovery of alternative NPC therapies. However, further research is necessary before such new therapeutic strategies can be fully realized. New cancer therapeutic strategies, induce p53-dependent actions and currently ongoing clinical trials for drugs against human cancers have also been mentioned in the review. This study suggests that the development of effective cancer therapeutics is still in progress. Although Nutlin-3 is far from ready for its clinical use for NPC, it is still an attractive alternative drug that should be given attention and explored further, given the poor prognosis and limited treatment choices for NPC.

This article is open access and can be downloaded from: http://www.eurekaselect.com/154246

Testimonial by Gina Paola Domínguez Moré!

Print

Contributed Article: “Pharmacokinetics of Botanical Drugs and Plant Extracts

New Issue :: Mini-Reviews in Medicinal Chemistry 17, Issue 7

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

mrmc

Articles from the journal Mini-Reviews in Medicinal Chemistry 17, Issue 7:

For details on the articles, please visit this link :: http://bit.ly/2ti3QMD

 

 

 

 

 

Highlighted Article Flyer for the journal “Mini-Reviews in Medicinal Chemistry”

MRMC-Articles-17 -18-2017-Karina Vázquez

http://www.eurekaselect.com/150897/article

Upcoming Thematic Issue – An Approach to Heterocyclic-Fused Quinone and Anthraquinone Derivatives: Synthesis, Isolation and Theoretical Calculations for Treatment of Chronic Diseases

MRMC- THEMATIC FLYER -Eduardo Sobarzo-Sánchez

http://www.eurekaselect.com/633/journal/mini-reviews-medicinal-chemistry

New Issue :: Mini-Reviews in Medicinal Chemistry 17, Issue 6

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

mrmc

Articles from the journal Mini-Reviews in Medicinal Chemistry 17, Issue 6:

For details on the articles, please visit this link :: http://bit.ly/2qqbUEC

 

Testimonial by Manojit Pal!

Manojit Pal

Contributed Article: “Ultrasound assisted synthesis of quinoline derivatives in the presence of SnCl2•2H2O as a precatalyst in water: evaluation of their antibacterial activities